Proteomics reveals protein profile changes in cyclooxygenase-2 inhibitor-treated endometrial cancer cells

International Journal of Gynecological Cancer

Volumn 19, Issue 3, 2009, Pages 326-333

  Yi, Zhang ^a   Jingting, Cai ^a   Yu, Zhang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cyclooxygenase 2 inhibitor; Endometrial cancer; Proteomics; Two dimensional electrophoresis

Indexed keywords

ALPHA ENOLASE; CYCLOOXYGENASE 2; HEAT SHOCK PROTEIN 70; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; MATRIGEL; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN DISULFIDE ISOMERASE; TETRAZOLIUM; TROPOMYOSIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL INVASION; CELL LINE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENDOMETRIUM; ENDOMETRIUM CANCER; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; NITROBENZENES; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SULFONAMIDES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 68149161644     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e31819f1b4d     Document Type: Article

References (58)

1. Parker SL, Tong T., Bolden S., et al. Cancer statistics. 1996, CA Cancer J Clin. 1996;46:5-27.
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10-17.
3. Rose PG. Endometrial carcinoma. N Engl J Med. 1996;335: 640-649.
4. Rissanen H., Knekt P., Järvinen R., et al. Serum fatty acids and breast cancer incidence. Nutr Cancer. 2003;45:168-175.
5. Bartsch H., Nair J., Owen RW. Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers. Carcinogenesis. 1999;20:2209-2218.
6. Rose DP, Connolly JM. Dietary fat, fatty acids, and prostate cancer. Lipids. 1992;27:798-803.
7. 2 a reduces trophoblast invasion and matrix metalloproteinase activity. Hypertension. 2000;35:1307-1313.
8. Imamura H., Takao S., Aikou T. A modified invasion-3-(4,5- dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide assay for quantitating tumor cell invasion. Cancer Res. 1994;54:3620-3624.
9. Deshane J., Chaves L., Sarikonda KV, et al. Proteomics analysis of rat brain protein modulations by grape seed extract. J Agric Food Chem. 2004;52:7872-7883.
10. Berndt P., Hobohm U., Langen H. Reliable automatic protein identification from matrix-assisted laser desorption/ionization mass spectrometric peptide fingerprints. Electrophoresis. 1999;20:3521-3526.
11. Ohno Y., Ohno S., Suzuki N., et al. Role of cyclooxygenase-2 in immunomodulation and prognosis of endometrial carcinoma. Int J Cancer. 2005;114:696-701.
12. Tsujii M., DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493-501.
13. Kase S., Osaki M., Honjo S., et al. Expression of cyclooxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas. Virchows Arch. 2003;442:129-135.
14. Fujiwaki R., Iida K., Kanasaki H., et al. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol. 2002;33:213-219.
15. Tsujii M., Kawano S., DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997;94:3336-3340.
16. Pockaj BA, Basu GD, Pathangey LB, et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 2004;11:328-339.
17. Ohno S., Ohno Y., Suzuki N., et al. Cyclooxygenase-2 expression correlates with apoptosis and angiogenesis in endometrial cancer tissue. Anticancer Res. 2007;27:3765-3770.
18. Nasir A., Boulware D., Kaiser HE, et al. Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy. In Vivo. 2007;21:35-43.
19. Ferrandina G., Legge F., Ranelletti FO, et al. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer. 2002;95:801-807.
20. Lambropoulou M., Alexiadis G., Limberis V., et al. Clinicopathologic and prognostic significance of cyclooxygenase-2 expression in endometrial carcinoma. Histol Histopathol. 2005;20:753-759.
21. Sawaoka H., Tsuji S., Tsujii M., et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest. 1999;79: 1469-1477.
22. Tendo M., Yashiro M., Nakazawa K., et al. Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells. Cancer Sci. 2005;96:451-455.
23. Yazawa K., Tsuno NH, Kitayama J., et al. Selective inhibition of cyclooxygenase-2 inhibits colon cancer cell adhesion to extracellular matrix by decreased expression of beta1 integrin. Cancer Sci. 2005;96:93-99.
24. Moore C., Perry AC, Love S., et al. Sequence analysis and immunolocalisation of phosphatidylethanolamine binding protein (PBP) in human brain tissue. Brain Res Mol Brain Res. 1996;37:74-78.
25. Hengst U., Albrecht H., Hess D., et al. The phosphatidylethanolamine binding protein is the prototype of a novel family of serine protease inhibitors. J Biol Chem. 2001;276:535-540.
26. Schoentgen F., Jolles P. From structure to function: possible biological roles of a new widespread protein family binding hydrophobic ligands and displaying a nucleotide binding site. FEBS Lett. 1995;369:22-26.
27. Akaishi J., Onda M., Asaka S., et al. Growth-suppressive function of phosphatidylethanolamine-binding protein in anaplastic thyroid cancer. Anticancer Res. 2006;26:4437-4442.
28. Li HZ, Wang Y., Gao Y., et al. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol Cancer Res. 2008;6:917-928.
29. Takimoto M., Tomonaga T., Matunis M., et al. Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promoter, in vitro. J Biol Chem. 1993;268:18249-18258.
30. Michelotti EF, Michelotti GA, Aronsohn AI, et al. Heterogeneous nuclear ribonucleoprotein K is a transcription factor. Mol Cell Biol. 1996;16:2350-2360.
31. Carpenter B., McKay M., Dundas SR, et al. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer. 2006;95:921-927.
32. Ostrowski J., Bomsztyk K. Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation. Br J Cancer. 2003;89:1493-1501.
33. He P., Naka T., Serada S., et al. Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci. 2007;98:1234-1240.
34. Wong CS, Wong VW, Chan CM, et al. Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. Oncol Rep. 2008;20:89-98.
35. Mikuriya K., Kuramitsu Y., Ryozawa S., et al. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography - mass spectrometry/mass spectrometry. Int J Oncol. 2007;30:849-855.
36. Malorni L., Cacace G., Cuccurullo M., et al. Proteomic analysis of MCF-7 breast cancer cell line exposed to mitogenic concentration of 17 beta-estradiol. Proteomics. 2006;6:5973-5982.
37. Kim W., Oe Lim S., Kim JS, et al. Comparison of proteome between hepatitis B virus - and hepatitis C virus-associated hepatocellular carcinoma. Clin Cancer Res. 2003;9:5493-5500.
38. Wang XP, Qiu FR, Liu GZ, et al. Correlation between clinicopathology and expression of heat shock protein 70 and glucose-regulated protein 94 in human colonic adenocarcinoma. World J Gastroenterol. 2005;11:1056-1059.
39. Jaattela M., Wissing D., Kokholm K., et al. Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J. 1998;17: 6124-6134.
40. Mosser DD, Caron AW, Bourget L., et al. Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. Mol Cell Biol. 1997;17:5317-5327.
41. Takashima M., Kuramitsu Y., Yokoyama Y., et al. Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma. Proteomics. 2003;3:2487-2493.
42. Zhao ZG, Shen WL. Heat shock protein 70 antisense oligonucleotide inhibits cell growth and induces apoptosis in human gastric cancer cell line SGC-7901. World J Gastroenterol. 2005;11:73-78.
43. Pollack R., Osborn M., Weber K. Patterns of organization of actin and myosin in normal and transformed cultured cells. Proc Natl Acad Sci U S A. 1975;72:994-998.
44. Kothakota S., Azuma T., Reinhard C., et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science. 1997;278:294-298.
45. Mills JC, Stone NL, Pittman RN. Extranuclear apoptosis. The role of the cytoplasm in the execution phase. J Cell Biol. 1999;146: 703-708.
46. Glotzer M. The molecular requirements for cytokinesis. Science. 2005;307:1735-1739.
47. Yamaguchi H., Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta. 2007;1773: 642-652.
48. Stehn JR, Schevzov G., O'Neill GM, et al. Specialisation of the tropomyosin composition of actin filaments provides new potential targets for chemotherapy. Curr Cancer Drug Targets. 2006;6: 245-256.
49. Kanai S., Toh H., Hayano T., et al. Molecular evolution of the domain structures of protein disulfide isomerases. J Mol Evol. 1998;47:200-210.
50. Wilkinson B., Gilbert HF. Protein disulfide isomerase. Biochim Biophys Acta. 2004;1699:35-44.
51. Puig A., Gilbert HF. Protein disulfide isomerase exhibits chaperone and anti-chaperone activity in the oxidative refolding of lysozyme. J Biol Chem. 1994;269:7764-7771.
52. Fink AL. Chaperone-mediated protein folding. Physiol Rev. 1999;79:425-449.
53. Zai A., Rudd MA, Scribner AW, et al. Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide. J Clin Invest. 1999;103:393-399.
54. Root P., Sliskovic I., Mutus B. Platelet cell-surface protein disulphide-isomerase mediated S-nitrosoglutathione consumption. Biochem J. 2004;382:575-580.
55. Raturi A., Mutus B. Use of 2, 3-diaminonapthalene for studying denitrosation activity of protein disulfide isomerase. Anal Biochem. 2004;326:281-283.
56. 1. Blood. 2003;102:2085-2092.
57. Turano C., Coppari S., Altieri F., et al. Proteins of the PDI family: unpredicted non-ER locations and functions. J Cell Physiol. 2002;193:154-163.
58. Goplen D., Wang J., Enger Pø, et al. Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res. 2006;66:9895-9902.